Acrivon Therapeutics, Inc. SEC filings ACRV
Acrivon Therapeutics, Inc. has 346 filings in SEC EDGAR's recent list, going back to Feb 12, 2021. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 12, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 29, 2024 | — |
| CORRESP | Letter to the SEC | Apr 24, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 19, 2024 | — |
| EFFECT | Filing | Dec 15, 2023 | — |
| CORRESP | Letter to the SEC | Dec 12, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 5, 2023 | — |
| DEFR14A | Filing | May 30, 2023 | — |
| SEC STAFF LETTER | Filing | Nov 9, 2022 | — |
| EFFECT | Filing | Nov 9, 2022 | — |
| CERT | Filing | Nov 8, 2022 | — |
| CORRESP | Letter to the SEC | Nov 7, 2022 | — |
| CORRESP | Letter to the SEC | Nov 7, 2022 | — |
| 8-A12B | Filing | Nov 7, 2022 | — |
| CORRESP | Letter to the SEC | Oct 17, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2022 | — |
| DRSLTR | Filing | Sep 22, 2022 | — |
| DRS/A | Filing | Sep 22, 2022 | — |
| SEC STAFF LETTER | Filing | Sep 14, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 12, 2022 | — |
| DRS | Filing | Aug 12, 2022 | — |
| D | Filing | Nov 23, 2021 | — |
| D | Filing | Feb 12, 2021 | — |
Showing 22 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACRV (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Watertown, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1781174
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.